Search

Certara Inc

Open

BrancheGesundheitswesen

6.81 -2.44

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

6.77

Max

6.99

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.9M

-8.8M

Verkäufe

3.3M

107M

KGV

Branchendurchschnitt

100.714

60.149

EPS

-0.06

Gewinnspanne

-8.196

Angestellte

1,515

EBITDA

-16M

16M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+12.41% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

258M

1.1B

Vorheriger Eröffnungskurs

9.25

Vorheriger Schlusskurs

6.81

Nachrichtenstimmung

By Acuity

19%

81%

32 / 340 Ranking in Healthcare

Certara Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Juli 2026, 19:31 UTC

News

Certara Inc partners with NVIDIA to enhance its AI biosimulation platform. Shares are higher, reflecting positive market sentiment around the collaboration.

Peer-Vergleich

Kursveränderung

Certara Inc Prognose

Kursziel

By TipRanks

12.41% Vorteil

12-Monats-Prognose

Durchschnitt 7.79 USD  12.41%

Hoch 10 USD

Tief 6 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Certara Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

3

Buy

6

Halten

0

Sell

Stimmung

By Acuity

32 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat